727 filings
Page 9 of 37
425
toccy9w09y ck13t9ut
1 Dec 22
Business combination disclosure
4:04pm
8-K
ejscia8t i8k1f0n4p
1 Dec 22
Kineta to Present KVA12123 VISTA Blocking Immunotherapy Program at Antibody Engineering and Therapeutics Conference
4:01pm
425
k3mju3v su84s
29 Nov 22
Business combination disclosure
4:03pm
8-K
o13bes3tvbisxvmiq
29 Nov 22
Kineta to Participate in JMP Securities Hematology and Oncology Summit
4:01pm
425
myajjhr
28 Nov 22
Business combination disclosure
4:03pm
8-K
f6n 4r6e6k
28 Nov 22
Regulation FD Disclosure
4:01pm
SEC STAFF
m8obk3u7k4 zh2f5s
17 Nov 22
SEC staff action: Order
12:00am
425
nqvcm5w44psmy660z
15 Nov 22
Business combination disclosure
4:03pm
8-K
37cp5pvjp5u frn2
15 Nov 22
Kineta Announces FDA Acceptance of Investigational New Drug (IND) Application for KVA12123 for the Treatment of Advanced Solid Tumors
4:02pm
425
wbrt rc1h8dmz5szz
14 Nov 22
Business combination disclosure
8:50am
8-K
hys4wn
14 Nov 22
Yumanity Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate Developments
8:37am
EFFECT
hdxvrt ssxn4
14 Nov 22
Notice of effectiveness
12:15am
424B3
vz5p4n8efg1c iu
10 Nov 22
Prospectus supplement
4:21pm
CORRESP
t4f8m
8 Nov 22
Correspondence with SEC
12:00am
CORRESP
e2su9dth7vp 69f4
4 Nov 22
Correspondence with SEC
12:00am
UPLOAD
a7vac8g0
1 Nov 22
Letter from SEC
12:00am
425
3mdzo48exfa5 81
27 Oct 22
Business combination disclosure
7:15am
8-K
qajbuta7w9 lu
27 Oct 22
Kineta to Present Pre-clinical Data on VISTA and CD27 Programs at SITC 2022 Annual Meeting
7:13am